- Home
- PSNL vs CMRX Comparison
PSNL vs CMRX Comparison
Compare PSNL & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- CMRX
- Stock Information
- Founded
- PSNL 2011
- CMRX 2000
- Country
- PSNL United States
- CMRX United States
- Employees
- PSNL N/A
- CMRX N/A
- Industry
- PSNL Medical Specialities
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- CMRX Health Care
- Exchange
- PSNL Nasdaq
- CMRX Nasdaq
- Market Cap
- PSNL 321.1M
- CMRX 77.0M
- IPO Year
- PSNL 2019
- CMRX 2013
- Fundamental
- Price
- PSNL $5.19
- CMRX $0.93
- Analyst Decision
- PSNL Strong Buy
- CMRX Strong Buy
- Analyst Count
- PSNL 4
- CMRX 1
- Target Price
- PSNL $6.81
- CMRX $11.00
- AVG Volume (30 Days)
- PSNL 439.4K
- CMRX 119.4K
- Earning Date
- PSNL 11-06-2024
- CMRX 11-08-2024
- Dividend Yield
- PSNL N/A
- CMRX N/A
- EPS Growth
- PSNL N/A
- CMRX N/A
- EPS
- PSNL N/A
- CMRX N/A
- Revenue
- PSNL $80,027,000.00
- CMRX $144,000.00
- Revenue This Year
- PSNL $10.85
- CMRX $3,040.12
- Revenue Next Year
- PSNL $8.77
- CMRX N/A
- P/E Ratio
- PSNL N/A
- CMRX N/A
- Revenue Growth
- PSNL 19.20
- CMRX N/A
- 52 Week Low
- PSNL $0.89
- CMRX $0.75
- 52 Week High
- PSNL $7.20
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- CMRX 60.78
- Support Level
- PSNL $4.54
- CMRX $0.80
- Resistance Level
- PSNL $5.35
- CMRX $0.98
- Average True Range (ATR)
- PSNL 0.30
- CMRX 0.05
- MACD
- PSNL 0.05
- CMRX 0.01
- Stochastic Oscillator
- PSNL 84.71
- CMRX 83.33
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.